Transcatheter aortic valve replacement: a review of current indications and outcomes

R I Med J (2013). 2014 Feb 3;97(2):38-41.

Abstract

In patients with symptomatic severe aortic stenosis, surgical aortic valve replacement (SAVR) improves survival, quality of life, and functional status compared with medical therapy. Based on the results of the randomized PARTNER Trial, Transcatheter Aortic Valve Replacement (TAVR) using the Edwards Sapien balloon expandable valve is now available in the United States for patients who are either inoperable due to anatomic concerns or severe medical co-morbidities, or as an alternative in patients considered high risk for SAVR. Fifty-six patients have been treated with TAVR at Rhode Island Hospital from March 2012 through October 2013 with similar outcomes to The PARTNER Trial and several large European registries. Second- generation valves and lower profile delivery systems designed to reduce the incidence of vascular complications, stroke, and perivalvular leak; and extension of TAVR to intermediate risk surgical patients, are under investigation.

Keywords: Aortic Stenosis; Transcather Aortic Valve Replacement.

Publication types

  • Review

MeSH terms

  • Aortic Valve Stenosis / surgery*
  • Heart Valve Prosthesis
  • Humans
  • Prosthesis Design
  • Transcatheter Aortic Valve Replacement*
  • Treatment Outcome